Cynvec

Cynvec is a biotechnology company that develops a proprietary oncolytic technology for the treatment of cancer.

Cynvec, an early stage biotech company based in New York City, was created in 2004 through the spin out of exclusively licensed IP from New York University focusing on the utility of the sindbis oncolytic viral vector in the treatment of cancer. It is based on the work of Dr. Daniel Meruelo, Ph.D., the world's leading authority on the virus and professor at NYU. Cynvec is in the process of preparing an investigational new drug application (IND) for our first product, CYN 101.